Peek Behind the Paper: RWE for assessing first-line treatments for BRAF mutation-positive cancer patients

Written by The Evidence Base

We peek behind the paper with the contributing study authors Jonathan Kish and Bruce Feinberg (both Cardinal Health, OH, USA): targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma. Please can you introduce yourself, your institution and your research focus? The Real World Evidence (RWE) and Insights group at Cardinal Health Specialty Solutions (OH, USA) conducts observational research studies in the fields of oncology, rheumatology and other specialty therapeutic areas. We are a team of epidemiologists, health services researchers, clinicians and biostatisticians. We support biopharmaceutical companies in their pursuits to generate data and evidence that illustrate unmet...

To view this content, please register now for access

It's completely free